BridgeBio Pharma

BBIO

Market cap $12.5B

- Accepted for Priority Review with PDUFA target action date of November 27, 2026, and poised to launch upon approval; being granted Priority Review by the FDA reiterates the serious unmet need for treatment options for the LGMD2I/R9 community

BridgeBio Pharma (NASDAQ:BBIO | BBIO Price Prediction) received a Neutral initiation from Citi Neutral on Tuesday, reflecting a measured stance on the company's transthyretin amyloid cardiomyopathy (ATTR-CM) franchise.

BridgeBio Pharma NASDAQ: BBIO executives used a BofA healthcare conference appearance in Las Vegas to reiterate confidence in the commercial trajectory of Attruby and outline expectations for three potential near-term product launches from the company's late-stage pipeline.

BridgeBio Pharma, Inc. (BBIO) Presents at Bank of America Global Healthcare Conference 2026 Transcript

- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1

-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p

PALO ALTO, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on May 6, 2026, the compensation committee of BridgeBio's board of directors approved equity grants to 52 new employees in restricted stock units for an aggregate of 115,007 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on May 16, 2027, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates.

BridgeBio Pharma, Inc. (BBIO) Q1 2026 Earnings Call Transcript

BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.7. This compares to a loss of $0.88 per share a year ago.

PALO ALTO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today its financial results for the first quarter ended March 31, 2026, and provided an update on Attruby's commercial progress.